Form 4: Candel Therapeutics Director Aguilar-Cordova Reduces Stake in Multiple Transactions

Director Estuardo Aguilar-Cordova and related entities decrease their holdings in Candel Therapeutics through a series of transactions between October 24 and October 28, 2024.

Summary

• Estuardo Aguilar-Cordova, a director and 10% owner of Candel Therapeutics, Inc. (CADL), has reported multiple transactions involving the disposal of CADL shares.
• On October 24, 2024, Aguilar-Cordova disposed of 16,427 shares at $5.53 and 1,194 shares at $5.72.
• On October 25, 2024, he disposed of 1,597 shares at $5.80.
• On October 28, 2024, he disposed of 11,711 shares at $5.58.
• Following these transactions, Aguilar-Cordova directly owns 888,532 shares.
• Additionally, he indirectly owns 2,074,942 shares through the Estuardo Aguilar-Cordova 2020 Irrevocable Trust, 2,013,100 shares through the Laura K. Aguilar 2020 Irrevocable Trust, 874,943 shares through the LKA 2022 Revocable Trust, and 171,335 shares jointly with his spouse.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the director selling shares, which could indicate a lack of confidence or a need for liquidity. However, without more context, it's difficult to assess the full impact.

Negatives

• A director is selling shares, which could be interpreted negatively by the market.

Risks

• Continued selling by insiders could put downward pressure on the stock price.

Industry Context

Insider selling is a common occurrence, but the market often scrutinizes the timing and reasons behind such transactions. It's important to consider the overall context of the company's performance and industry trends.

Stakeholder Impact

• Shareholders may react to the insider selling, potentially leading to price volatility.
• The transactions could influence investor sentiment regarding the company's prospects.

Key Dates